digoxin and pentaformylgitoxin

digoxin has been researched along with pentaformylgitoxin* in 7 studies

Other Studies

7 other study(ies) available for digoxin and pentaformylgitoxin

Article	Year
[Postprandial delay of drug absorption in a gitoformate model]. Arzneimittel-Forschung, 1987, Volume: 37, Issue:12 Oral absorption of gitoformate (Dynocard), a non-renal-dependent cardiac glycoside, was investigated in 8 healthy subjects aged 23-45 years. Plasma concentration-time profiles were obtained once following a 12-h period of fasting, then after intake of a standard high protein meal. The half-life of absorption t1/2a, Cmax and tmax, half-life of elimination t1/2z, and area under the curve (AUC) were compared to evaluate the influence on the bioavailability of gitoformate. t1/2a in the fasting condition (0.36 +/- 0.43 h) is increased when gitoformate is applied after a high protein meal 1.12 +/- 1.12 h). Correspondingly, fasting maximum concentrations are already achieved after 1.4 +/- 1.2 h, but only after 4.8 +/- 1.8 h following the intake of a standard meal. Comparison of AUC (0-168 h) showed that the bioavailability was reduced by 25% after meals. Topics: Absorption; Administration, Oral; Adult; Biological Availability; Digoxin; Fasting; Female; Food; Half-Life; Humans; Isomerism; Male	1987
[Gitoformate and digitoxin as alternatives to kidney-dependent glycosides in the therapy of cardiac insufficiency]. Arzneimittel-Forschung, 1984, Volume: 34, Issue:8 Kidney independent glycosides offer a high measure of therapeutic safety in comparison with kidney dependent glycosides. The intoxication rate lies between 4 and 6%. The pharmacokinetic properties of pentaformylgitoxin (INN: gitoformate) are comparable with those for digitoxin. The active glycoside 16-formylgitoxin (INN: gitaloxin) is formed by rapid deformylation of the formyl residue on the sugar chain. The maintenance dose of 0.06 mg daily, based on the half-life, produces therapeutic concentrations in the range 6-30 ng/ml. The required loading dose, as for digitoxin, amounts to 10 times the maintenance dose. Topics: Cardiac Glycosides; Digitoxin; Digoxin; Heart Failure; Humans; Hypokalemia; Kidney; Protein Binding; Risk; Serum Albumin	1984
[Circadian aspects of the heart rate in atrial fibrillation patients: the comparative effect of digoxin and pentaformylgitoxin]. Cardiologia (Rome, Italy), 1983, Volume: 28, Issue:12 Topics: Atrial Fibrillation; Circadian Rhythm; Digoxin; Drug Evaluation; Electrocardiography; Heart Rate; Humans; Isomerism; Male; Middle Aged	1983
[Circadian aspects of heart rate in patients with atrial fibrillation: comparative influence of digoxin and pentaformylgitoxin]. Cardiologia (Rome, Italy), 1983, Volume: 28, Issue:12 Topics: Atrial Fibrillation; Circadian Rhythm; Digoxin; Heart Rate; Humans; Male; Middle Aged	1983
[Pharmacokinetics of gitoformate in subjects with renal insufficiency under dialysis treatment]. Bollettino della Societa italiana di cardiologia, 1981, Volume: 26, Issue:12 Topics: Digoxin; Humans; Kidney Failure, Chronic; Male; Renal Dialysis	1981
[Pharmacokinetics and pharmacodynamics of gitoformate in subjects with atrial fibrillation]. Bollettino della Societa italiana di cardiologia, 1981, Volume: 26, Issue:12 Topics: Adult; Aged; Atrial Fibrillation; Digoxin; Electrocardiography; Humans; Male; Middle Aged	1981
[Gitoformate in chronic renal insufficiency: pharmacokinetic aspects]. Bollettino della Societa italiana di cardiologia, 1979, Volume: 24, Issue:2 Topics: Adult; Digoxin; Female; Humans; Kidney Failure, Chronic; Male; Middle Aged	1979